MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Revance Therapeutics Operating Income 2011-2026 | RVNC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Revance Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -317 M | -342 M | -275 M | -273 M | -164 M | -143 M | -120 M | -88.2 M | -72.3 M | -52 M | -38.2 M | -43.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -38.2 M | -342 M | -161 M |
Quarterly Operating Income Revance Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -32.3 M | -34.5 M | -46.8 M | - | -37.6 M | -56.3 M | -46.7 M | - | -77.5 M | -57.8 M | -62.2 M | - | -72.7 M | -70.3 M | -70 M | - | -77.1 M | -57.1 M | -61 M | -46.2 M | -42.5 M | -39.1 M | -36.6 M | -38.4 M | -33.6 M | -34.9 M | -35.7 M | - | -30.7 M | -26.8 M | -27.1 M | - | -17.7 M | -24.1 M | -19.7 M | - | -18.8 M | -16.6 M | -15.2 M | - | -13.8 M | -12.9 M | -11.5 M | - | -8.27 M | -11.3 M | -9.68 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.27 M | -77.5 M | -37.7 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 21.66 | 1.14 % | $ 1.01 B |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
231 M | $ 22.33 | 1.66 % | $ 3.7 B | USA |
 |
Esperion Therapeutics
ESPR
|
60.3 M | $ 1.94 | 1.31 % | $ 403 M | USA |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
Galectin Therapeutics
GALT
|
-20.1 M | $ 2.38 | 2.33 % | $ 152 M | USA |
 |
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Greenwich LifeSciences
GLSI
|
-16 M | $ 24.07 | -0.58 % | $ 313 M | USA |
 |
Heron Therapeutics
HRTX
|
-2.54 M | $ 1.18 | -0.84 % | $ 197 M | USA |
 |
ImmuCell Corporation
ICCC
|
1.65 M | $ 8.26 | -1.07 % | $ 74.6 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-33.3 M | - | -11.43 % | $ 502 K | USA |
 |
Innate Pharma S.A.
IPHA
|
-47.8 M | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Inventiva S.A.
IVA
|
-52.1 M | $ 5.11 | -0.78 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
-45.9 M | $ 0.29 | -25.25 % | $ 676 K | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-30 M | - | 17.91 % | $ 11.1 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-112 M | $ 19.09 | -2.75 % | $ 1.03 B | Britain |
 |
BioNTech SE
BNTX
|
15.3 B | $ 102.36 | -2.94 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.11 | 0.61 % | $ 439 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 23.18 | -0.34 % | $ 2.95 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.43 | -0.7 % | $ 381 M | Britain |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-22.6 M | $ 240.72 | 4.09 % | $ 4.4 B | USA |
 |
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.9 | -0.34 % | $ 4.77 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | USA |